In 2006, researchers in Japan showed that adult cells could be reprogrammed into induced pluripotent stem cells, which behave like embryonic stem cells. In principle, a patient’s skin or blood cells can be turned into iPSCs and then into almost any cell type, such as retina, nerve, or heart cells.
A few patients have received cells made this way. In 2017, a single patient in Japan with macular degeneration received a sheet of retinal cells grown from her own iPSCs. In 2020, a single patient in the United States with Parkinson’s disease received dopamine-producing cells made from his own iPSCs. Both reports described one person each.
Making cells for one patient takes months and is very expensive, so most current trials use cells from a single donor line instead. In 2025, two small early trials published in Nature reported that dopamine-producing cells made from pluripotent stem cells survived and appeared safe in people with Parkinson’s disease. Larger trials are under way.
Most regenerative treatment outside hospitals uses mesenchymal stem cells (MSCs). At OmniStem, these are umbilical cord MSCs (UC-MSCs) from screened donor tissue, prepared in standardized batches with documented testing for identity, cell count, viability, and sterility.
UC-MSCs carry low levels of the markers that trigger immune rejection, so they can be given to a patient without genetic matching. Their effect comes mainly from the signals they release, which lower inflammation and adjust immune activity. Our guide to mesenchymal stem cells explains how they work.
What is personalized is the plan. After reviewing a patient’s history, imaging, and goals, a physician decides:
Personalizing the plan does not change what the evidence shows for a condition. Evidence for MSC therapy differs widely: it is strongest for knee osteoarthritis and remains early for most neurological and autoimmune conditions.
When a clinic describes treatment as personalized, ask what that means in practice:
If a clinic says it will profile your genes or grow cells specifically for you, ask where that work is done and how long it takes. Our guide to choosing a stem cell clinic covers these questions in more detail.
Start with a medical review
At OmniStem, every plan starts with a physician reviewing your records through the Regenerative Evaluation.
Start Your EvaluationTakahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.
Mandai M, Watanabe A, Kurimoto Y, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. New England Journal of Medicine. 2017;376(11):1038-1046.
Schweitzer JS, Song B, Herrington TM, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson’s disease. New England Journal of Medicine. 2020;382(20):1926-1932.
Atkins HL, Bowman M, Allan D, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016;388(10044):576-585.
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell. 2016;19(2):154-157.